UK-US Trade Deal Benefits From Biologic Exclusivity ‘Commitment’
UK Currently In Talks For Post-EU Free Trade Agreement With US
The US Trade Representative Robert Lighthizer has intimated that a controversial provision requiring 10 years of biologic data exclusivity would not be contained in a proposed free trade agreement with the UK, as it seeks partners following its exit from the EU.
You may also be interested in...
The UK has published its negotiating mandate for talks on a free trade deal with the US. As expected, intellectual property protection figures prominently, but the life sciences industry sees little merit in the government’s approach. It also warns that the UK’s future relationship with the EU could lead to greater regulatory burdens and costs.
Responding to UK government statements on the country’s future approach to trade deals with non-EU nations, the BGMA has insisted that there must be no changes to patent and exclusivity provisions that would block market entry for generic and biosimilar medicines.
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.